Contraindicated in patients who have had a severe systemic reaction during prior administration of any equine gamma globulin preparation.
- TRADE NAME: Atgam (Pfizer)
- INDICATIONS: Management of allograft rejection in renal transplant patients, prophylaxis of moderate to severe aplastic anemia in patients who are unsuitable for bone marrow transplantation
- CLASS: Immunosuppressant
- HALF-LIFE: 3–9 days
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 08/20/2025
